Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aquaphor vs Miaderm for Acute Radiation Dermatitis in Breast Cancer
NCT05340673Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Miaderm in radiation dermatitis (2 arms), sponsored by City of Hope. Primary endpoint: Acute Radiation Dermatitis. Started Sep 2022; status: active, not recruiting.
02
Drugs
Miaderm
03
Conditions
radiation dermatitis
Beyond the preview
Go deeper on NCT05340673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05340673.